
    
      Patients in this study will receive nivolumab in combination with the standard of care
      dose-adjusted EPOCH (etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide) for
      six 21 day cycles. Patients will then have an autologous stem cell transplant or continue to
      receive maintenance therapy with nivolumab.
    
  